Pfizer (PFE) Other financing activities (2009 - 2026)

Pfizer (PFE) has reported Other financing activities for 18 consecutive years, with -$27.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other financing activities fell 28.57% year-over-year to -$27.0 million in Q2 2026; TTM through Jun 2026 was -$392.0 million, a 56.2% increase from a year earlier, with the FY2025 full-year figure at -$458.0 million, up 2.35% from the prior year.
• Other financing activities was -$27.0 million for Q2 2026 at Pfizer, up from -$284.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $154.0 million in Q3 2022 and troughed at -$501.0 million in Q2 2022.
• A 5-year average of -$186.7 million and a median of -$101.5 million in 2023 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities sank 190.91% in 2023 and jumped 91.65% in 2025, its largest moves.
• Over 5 years, Other financing activities stood at $154.0 million in 2022, then plunged by 111.69% to -$18.0 million in 2023, then plunged by 2427.78% to -$455.0 million in 2024, then soared by 90.55% to -$43.0 million in 2025, then jumped by 37.21% to -$27.0 million in 2026.
• The last three Other financing activities figures came in at -$27.0 million (Q2 2026), -$284.0 million (Q1 2026), and -$43.0 million (Q4 2025), per Business Quant data.